Altimmune's management will attend two investor conferences in November 2025, discussing peptide-based therapeutics for liver diseases.
Quiver AI Summary
Altimmune, Inc., a biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases, announced its participation in upcoming investor conferences. Management will engage in one-on-one meetings and hold fireside chats at the Stifel 2025 Healthcare Conference on November 12 and the Jefferies Global Healthcare Conference on November 20. Both sessions will be webcasted and accessible via the company's website. Altimmune's primary product candidate is pemvidutide, designed to treat metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. Further details can be found on their website.
Potential Positives
- Participation in notable investor conferences showcases Altimmune's commitment to engaging with the investment community and increasing visibility.
- Webcast availability of conference sessions may enhance accessibility for a broader audience, potentially attracting more investor interest.
- Focus on a late clinical-stage biopharmaceutical product, pemvidutide, emphasizes the company's advancements in addressing significant health issues, which could lead to competitive advantages in the market.
Potential Negatives
- Company is described as “late clinical-stage,” which may raise concerns about the progress and viability of its product candidates.
- Investors may perceive the need for a series of one-on-one meetings and conferences as a sign of a search for capital or support, suggesting current challenges.
- Limited information about the success or failure of their lead product candidate, pemvidutide, may generate uncertainty and skepticism among potential investors.
FAQ
What are the upcoming investor conferences for Altimmune?
Altimmune will participate in the Stifel 2025 Healthcare Conference on November 12 and the Jefferies Global Healthcare Conference on November 20, 2025.
How can I access the conference sessions?
The conference sessions will be webcast and can be accessed via the Events section of the Altimmune website.
What is Altimmune's lead product candidate?
Altimmune's lead product candidate is pemvidutide, a dual receptor agonist for treating metabolic dysfunction-associated steatohepatitis and other conditions.
What diseases does Altimmune focus on?
Altimmune develops therapeutics for liver and cardiometabolic diseases, including metabolic dysfunction-associated steatohepatitis and alcohol-related liver diseases.
Who can I contact for investor relations at Altimmune?
For investor inquiries, contact Lee Roth at Burns McClellan via phone at 646-382-3403 or email at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALT Hedge Fund Activity
We have seen 93 institutional investors add shares of $ALT stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMERIPRISE FINANCIAL INC removed 1,330,057 shares (-92.1%) from their portfolio in Q2 2025, for an estimated $5,147,320
- MARSHALL WACE, LLP removed 1,146,238 shares (-98.1%) from their portfolio in Q2 2025, for an estimated $4,435,941
- BELLEVUE GROUP AG removed 1,056,793 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,089,788
- MILLENNIUM MANAGEMENT LLC removed 1,033,005 shares (-93.0%) from their portfolio in Q2 2025, for an estimated $3,997,729
- SCHRODER INVESTMENT MANAGEMENT GROUP removed 961,884 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,722,491
- CAPTION MANAGEMENT, LLC added 941,917 shares (+2423.6%) to their portfolio in Q2 2025, for an estimated $3,645,218
- FEDERATED HERMES, INC. removed 915,383 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $3,450,993
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALT Analyst Ratings
Wall Street analysts have issued reports on $ALT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/10/2025
- UBS issued a "Buy" rating on 08/13/2025
To track analyst ratings and price targets for $ALT, check out Quiver Quantitative's $ALT forecast page.
$ALT Price Targets
Multiple analysts have issued price targets for $ALT recently. We have seen 5 analysts offer price targets for $ALT in the last 6 months, with a median target of $15.0.
Here are some recent targets:
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $12.0 on 10/20/2025
- Mayank Mamtani from B. Riley Securities set a target price of $18.0 on 08/13/2025
- Eliana Merle from UBS set a target price of $24.0 on 08/13/2025
- Jonathan Wolleben from JMP Securities set a target price of $15.0 on 07/10/2025
Full Release
GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for one-on-one meetings at the following investor conferences:
-
Stifel 2025 Healthcare Conference
Wednesday, November 12, 2025
Fireside Chat at 10:00 a.m. ET
-
Jefferies Global Healthcare Conference
Thursday, November 20, 2025
Fireside Chat at 9:30 a.m. GMT
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com .
Follow @Altimmune, Inc. on
LinkedIn
Follow @AltimmuneInc on
X
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
[email protected]
Media Contact:
Elliot Fox
Real Chemistry
[email protected]
This press release was published by a CLEAR® Verified individual.
